Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis.

AIM: To evaluate the impact of postoperative injection into the hepatic artery of 131-iodine-labeled lipiodol on disease-free and overall survival rates in patients who underwent liver surgical resection for hepatocellular carcinoma. METHODS: Ten consecutive patients with HCV (hepatitis C virus)-related cirrhosis who underwent liver surgical resection for hepatocellular carcinoma were treated with adjuvant injection of 131-iodine-labeled lipiodol. They were matched with 20 HCV-positive cirrhotic controls who underwent liver resection alone; patients were paired in terms of age, Child-Pugh class, tumor size, microscopic vascular invasion, tumor histological pattern, presence of satellite nodules and type of surgical resection. Recurrence was defined as the development of a new hypervascularizated nodule in the liver. RESULTS: No significant differences were found between the two groups in clinical, biologic and histologic characteristics, except a lower platelet count in the control group. None of the treated patients developed an intrahepatic recurrence until the 15th month from liver resection, whereas recurrences occurred in nine of the 20 patients in the control group (p=0.01). From 18 months onwards, recurrences appeared also in the treated patients, and after 36 months of follow-up both recurrence rate and overall survival were not significantly different between the two groups. CONCLUSIONS: Intrahepatic injection of 131-iodine-labeled lipiodol improves the disease-free survival rate following liver resection of hepatocellular carcinoma in the short term up to 15 months; this advantage fades, however, away after 36 months.     

肝动脉化疗和栓塞治疗中、晚期肝癌156例报告

从1990年8月至1994年10月，我们用肝动脉化疗、栓塞术治疗156例中、晚期肝癌。随访129例，一年生存率为32．56％，半年生存率为55．8％，治疗总有效率为76％。21例接受Ⅱ期外科手术切除肿瘤，病理检查证实少数病例肿瘤完全坏死。大多数病例肿瘤明显坏死，残余少量癌细胞。作者认为：充分栓塞肝动脉和合理安排化疗剂量与周期可提高疗效；影响栓塞效果的因素有肿瘤血供分型、侧枝循环形成和肿瘤动一静脉瘘形成。     

Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol

SM-11355 is a platinum complex developed to treat hepatocellular carcinoma (HCC). It is administered via the hepatic artery, using a carrier, lipiodol, that consists of ethyl esters of iodized poppy seed oil. We have performed a phase I clinical trial of an SM-11355-lipiodol formulation in 11 HCC patients, in order to investigate the maximum allowable dose and to maximize the efficacy and safety of the drug in the treatment of HCC. The SM-11355 arterial infusion suspension was administered at doses of 6, 12 and 20 mg ml(-1) in a maximum lipiodol volume of 6 ml. An antitumour efficacy rating of complete response was achieved for one patient and a partial response rating was achieved for a second patient, giving an overall response rate of 18.2%. Anorexia, nausea and vomiting, pyrexia, thrombocytopenia and increases in AST, ALT and total bilirubin were observed as adverse effects, but each was transient and each patient had recovered completely by 4 weeks after drug administration. Hence, we concluded that the maximum allowable dose was not reached in this study. Overall, our results suggest that SM-11355 is effective in treating HCC and we suggest that the dose for early phase II trials should be 20 mg ml(-1).     

不同栓塞剂介入治疗肝海绵状血管瘤的疗效

目的: 评价经肝动脉插管不同栓塞剂治疗肝海绵状血管瘤的疗效.材料和方法: 56例肝海绵状血管瘤患者分为3组,A组15人,栓塞剂鱼肝油酸钠 碘化油;B组18人,栓塞剂为8mg平阳霉素 碘化油乳化液栓塞组,C组23人,栓塞剂为8mg平阳霉素 碘化油乳化液 明胶海绵颗粒.全部患者于栓塞后3及6个月行CT复查,评价瘤体萎缩情况.结果: A组和B组疗效无差异,C组比A,B组疗效好(P<0.01).结论: 应用平阳霉素作为血管内皮损伤剂和碘化油栓塞海绵状血管瘤,再以明胶海绵阻断供载瘤供血动脉干为最佳安全有效治疗方法.     

平阳霉素碘油乳剂经肝动脉栓塞肝海绵状血管瘤的疗效观察

目的观察平阳霉素碘油乳剂（PLE）经肝动脉栓塞肝海绵状血管瘤的疗效。方法超选择性肝动脉插管，注入PLE栓塞肝海绵状血管瘤（CHL），术后6个月CT复查，判定疗效。结果术后6个月血管瘤体积明显缩小（P〈0.01），且未出现严重并发症。结论利用PLE经动脉介入栓塞治疗CHL，是一种安全、有效的方法。     

Lipiodolization for unresectable hepatocellular carcinoma: An analysis of 205 patients using univariate and multivariate analysis

Since 1982 we have developed and successfully performed lipiodolization on 205 patients with unresectable hepatocellular carcinoma. The 1-, 2-, 3-, 4-, and 5-year survival rates were 55.6%, 31.7%, 16.3%, 8.7%, and 2.9%, respectively, while the median survival was 413 days, and 20 patients survived longer than 3 years after the first lipiodolization. Our study demonstrated that the factors for a comparatively good prognosis were as follows: patient older than 50 years, nodular type hepatocellular carcinoma <5 cm in diameter, negative tumor invasion of portal vein, <10 intrahepatic metastases, serum alpha-fetoprotein level <400 ng/ml, and Okuda stage I. Lipiodolization did not cure hepatocellular carcinoma. It did, however, in this study, achieve a prolongation of the patient's survival. © 1994 Wiley-Liss, Inc.     

336例原发性中晚期肝癌介入治疗中碘油用量及临床分析

目的：探讨中晚期肝癌介入治疗中导管位置与碘油量的关系以及碘油用量对临床疗效、副作用的影响。方法：回顾采用肝固有动脉给药的病例86例及高度选择性栓塞治疗的肝癌250例,并比较二者的疗效、副作用与碘用量的关系。结果：本组病例肝癌大小3－15cm,86例为肝固有动脉给药治疗1－3次者,碘油用量5－10ml/次,肿瘤明显缩小20例（23％）,2年生存5例（6％）。高度选择性栓塞治疗1－3次的250例,碘油用量15－40ml／次,肿瘤明显缩小163例（65％）,2年生存78例（31％）。结论：肝癌超选择性栓塞的碘油用量与疗效成正比,副反应随碘油用量轻微增高;固有动脉栓塞疗效较差、副作用大。     

姜黄素对肝癌大鼠碘油栓塞后信号传导与转录激活因子3及其磷酸化形式表达的影响

目的 研究姜黄素对大鼠移植性肝癌模型碘油栓塞后生存时间、肿瘤生长率及对信号转导和转录活化因子3 (STAT3)及其磷酸化形式pSTAT3表达的影响.方法 建立SD大鼠移植性肝癌模型,将建模成功SD大鼠随机分为模型组、碘油组、姜黄素组、碘油联合姜黄素组,根据组别经肝动脉分别灌注生理盐水、超液态碘油和(或)姜黄素,观察实验动物的生存时间、肿瘤生长率,Western blot法检测肿瘤边缘组织中STAT3及pSTAT3表达水平.结果 碘油联合姜黄素组与模型组、姜黄素组、碘油组相比,生存时间明显延长(P＜0.01).姜黄素组、碘油组比较差异无统计学意义(P＞0.05),治疗后模型组、姜黄素组、碘油组肿瘤体积较治疗前明显增大(P＜0.01),姜黄素组、碘油组肿瘤生长率均低于模型组(P＜0.01);碘油联合姜黄素组肿瘤体积与治疗前相比无明显改变(P＞0.05),肿瘤生长率明显低于其它3组(P＜0.0l).碘油联合姜黄素组STAT3及pSTAT3表达水平明显低于模型组.结论 姜黄素可抑制大鼠移植性肝癌模型碘油栓塞后肿瘤组织中STAT3及其磷酸化形式pSTAT3表达水平,同时本实验提示姜黄素与碘油栓塞联合治疗肝癌可能具有良好的应用前景.     

表柔比星分别联合碘油与Hepasphere载药微球对肝癌患者TACE的疗效分析

目的:研究表柔比星分别联合碘油与Hepasphere载药微球对经皮肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE）治疗肝癌患者的疗效及预后分析。方法:选取病例被随机分为两组,分别注射表柔比星与碘油（A组）、表柔比星与Hepasphere微球混合液（B组）。1个月后对比术前及术后肝肾功、AFP,并采用mRECIST标准［疾病缓解率（CR+PR）、疾病控制率（CR+PR+SD）］对比两组之间差别。结果:A、B组患者术前、术后肝肾功等化验指标数值,组间和组内对比无统计学差异（P>0.05）;A、B组患者TACE治疗前AFP差异无统计学意义（P>0.05）,术后AFP差异有统计学意义（P<0.05）;两组患者疾病缓解率、疾病控制率差异有统计学意义（P<0.05）。结论:表柔比星联合Hepasphere载药微球可以提高肝癌患者TACE的疗效。     

The FLUSH trial--flushing with lipiodol for unexplained (and endometriosis-related) subfertility by hysterosalpingography: a randomized trial

BACKGROUND: To assess the effectiveness of flushing with the oil-soluble contrast medium lipiodol in women with unexplained infertility. METHODS: An open randomized controlled trial design in a single centre secondary and tertiary level infertility service setting. A total of 158 women with unexplained infertility were stratified into two populations: 96 women without confirmed endometriosis and 62 women with endometriosis who had normal Fallopian tubes and ovaries. Randomization was computer-generated, with allocation concealment by opaque sequentially numbered envelopes. Lipiodol flushing was tested versus no intervention. The main outcome measures were clinical pregnancy (assessed at 6 months following randomization) and live birth. RESULTS: Lipiodol flushing resulted in a significant increase in pregnancy [48.0 versus 10.8%, relative risk (RR) 4.44, 95% confidence interval (CI) 1.61-12.21] and live birth (40.0 versus 10.8%, RR 3.70, 95% CI 1.30-10.50) rates versus no intervention for women with endometriosis, although there was no significant difference in pregnancy (33.3 versus 20.8%, RR 1.60, 95% CI 0.81-3.16) or live birth (27.1 versus 14.6%, RR 1.86, 95% CI 0.81-4.25) rates for women with unexplained infertility without confirmed endometriosis. CONCLUSIONS: Lipiodol flushing is an effective treatment for couples with unexplained infertility (based on meta-analysis data), but is particularly effective for women with endometriosis who have normal Fallopian tubes and ovaries.